Articles tagged "Hepatocellular carcinoma"

2019 American Transplant Congress
DOME: A New Strategy for Prioritizing Hepatocellular Carcinoma Patients on the Liver Transplant Waitlist
C. Rickert¹, M. Akan², Z. Leung³, J. F. Markmann¹, S. Tayur², H. Zhao³, H. Yeh¹
¹Massachusetts General Hospital, Boston, MA, ²Tepper School of Business, Carnegie Mellon University, Pittsburgh, PA, ³City University of Hong Kong, Hong Kong, China
*Purpose: Currently, adult HCC patients are prioritized for liver transplantation by receiving MELD exception points, determined primarily by time on waitlist without regard to actual…
2019 American Transplant Congress
Outcome Of Living Donor Liver Transplantation In Elderly Patients >65 Years With And Without Hepatocellular Carcinomas: A Retroepsective Analysis
A. Thorat, L. Jeng, S. Hsu, H. Yang, C. Yeh, T. Chen, K. Poon, P. Li
Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan
*Purpose: The elderly patients > 65 years with end-stage liver disease that require liver transplantation has been steadily increased over last decade in Taiwan and…
2019 American Transplant Congress
Adjuvant Immunotherapeutic Approach For Liver Transplant Recipients With Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells
M. Ohira¹, R. Hotta¹, Y. Imaoka¹, K. Sato¹, Y. Tanaka¹, A. G. Tzakis², S. Nishida³, H. Ohdan¹
¹Hiroshima University, Hiroshima, Japan, ²Cleveland Clinic Florida, Weston, FL, ³New York Medical College, Valhalla, NY
*Purpose: Although liver transplantation (LT) is a preferred treatment for selected patients with Hepatocellular carcinoma (HCC), HCC-recurrence would be a still important medical problem. Most…
2019 American Transplant Congress
Favorable Outcome of Pathologic Downstaging by Locoregional Treatment for Hepatocellular Carcinoma in Liver Transplantation
D. Kim, J. Lee, S. Kim, K. In, D. Joo, S. Kim, M. Kim
Severance hospital, Seoul, Korea, Republic of
*Purpose: There was no distinct guideline how to take into account the effect of pretransplant locoregional treatment (LRT) in hepatocellular carcinoma (HCC) staging system. The…
2019 American Transplant Congress
Prospective Multi-Regional Study of Down-Staging of Hepatocellular Carcinoma to within Milan Criteria before Liver Transplantation
N. Mehta¹, J. Guy², C. Frenette³, P. Tabrizian⁴, M. Hoteit⁵, R. Dhanasekaran⁶, J. Dodge¹, M. L. Holzner⁴, L. Frankul³, S. Florman⁴, N. Parikh⁷, F. Yao¹
¹UCSF, San Francisco, CA, ²CPMC, San Francisco, CA, ³Scripps Hospital, La Jolla, CA, ⁴Mt Sinai, New York, NY, ⁵U. Pennsylvania, Philadelphia, PA, ⁶Stanford, Palo Alto, CA, ⁷U. Michigan, Ann Arbor, MI
*Purpose: Recent studies from United Network of Organ Sharing (UNOS) Region 5 reported excellent outcomes after liver transplantation (LT) after successful down-staging in HCC patients…
2019 American Transplant Congress
Tumor Necrosis as a Result to Pre-Transplant Bridging Treatment for Hepatocellular Carcinoma and Its Effect on Post-Transplant Outcome
S. Radunz¹, A. Kirschner¹, J. M. Theysohn², C. Schotten³, T. Benkö¹
¹General, Visceral and Transplant Surgery, University Hospital Essen, Essen, Germany, ²Diagnostic and Interventional Radiology and Neurradiology, University Hospital Essen, Essen, Germany, ³Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany
*Purpose: As a bridge to liver transplantation, locoregional treatments are commonly employed in hepatocellular carcinoma (HCC) patients to prevent tumor progression during waiting time. Objective…
2019 American Transplant Congress
Outcomes of Liver Transplantation for Mixed Hepatocellular-Cholangiocarcioma
M. Najjar¹, K. Bruestle¹, P. Jiang¹, S. Robbins-Juarez¹, R. Hwang¹, A. Mathur¹, E. C. Verna¹, A. Griesemer¹, B. Samstein¹, T. Kato¹, Y. M. Saenger¹, K. J. Halazun², J. C. Emond¹
¹Columbia University Medical Center, New York, NY, ²Weill Cornell Medicine, New York, NY
*Purpose: Mixed hepatocholangiocarcinomas (HCC-CCA) are rare tumors with both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) differentiations. They are usually associated with a worse prognosis than…
2019 American Transplant Congress
Resource Utilization in Hepatocellular Carcinoma Liver Transplantation before and after the Six Month Wait Time
J. Sokolich¹, W. McClellan², J. Buggs¹, E. Rogers¹, K. Barber¹, K. Cocuy¹, A. Kumar²
¹Tampa General Hospital, Tampa, FL, ²University of South Florida, Tampa, FL
*Purpose: The purpose of this study was to determine any difference in resource utilization since the implementation of the mandatory six month wait-time policy for…
2019 American Transplant Congress
Predicting HCC Recurrence Following Liver Transplant – A Machine Learning Approach
L. F. Lau¹, W. Nelson², A. Gorgen¹, L. Erdman², P. Abreu¹, A. Goldenberg², G. Sapisochin¹
¹Department of Surgery, University of Toronto, Toronto, ON, Canada, ²The Center for Computational Medicine, The Hospital for Sick Children, Toronto, ON, Canada
*Purpose: The liver transplant listing criteria for hepatocellular carcinoma (HCC) is controversial. Policies aim to prevent tumor recurrence but it has been difficult to encompass…
2019 American Transplant Congress
Hepatocellular Carcinoma in Fontan Liver Disease
V. Lamm¹, J. Wedd², C. Haydek², C. Obineme², A. Noll², H. Veeramachaneni², M. Muftah², R. Ford²
¹Internal Medicine, Emory, Atlanta, GA, ²Emory, Atlanta, GA
*Purpose: To add to the clinical characteristics and outcomes of hepatocellular carcinoma (HCC) in post Fontan operation patients and present, to the best of our…